Amgen

Insurers, doctors battle over new heart disease drugs
CNBC
Fri, 09/8/17 - 09:30 am
insurers
cardiovascular disease
statins
PCSK9 inhibitors
Amgen
Regeneron
Sanofi
Repatha
Praluent
AstraZeneca, Amgen whip up some blockbuster excitement with a possible game-changing asthma drug
Endpoints
Thu, 09/7/17 - 09:33 am
AstraZeneca
Amgen
tezepelumab
asthma
The Only 2 Biotech Stocks With a Higher Dividend Yield Than the S&P 500
Motley Fool
Mon, 09/4/17 - 10:33 pm
biotech stocks
Amgen
Gilead Sciences
Key FDA Regulatory Events to Watch Out for in Sep 2017
Yahoo/Zacks.com
Mon, 09/4/17 - 10:31 pm
FDA
Mylan Labs
Herceptin
biosimilars
trastuzumab
Shingrix
GSK
Pfizer
Sutent
PTC Therapeutics
Translarna
Amgen
Allergan
Avastin
Is the System Rigged Against Biosimilars?
Motley Fool
Sat, 08/26/17 - 12:39 pm
biosimilars
Amgen
Amjevita
In cost debate, Amgen stands by Repatha's value
BioPharma Dive
Wed, 08/23/17 - 11:36 am
Amgen
Repatha
drug pricing
PCSK9 inhibitors
Praluent
Sanofi
Regeneron
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
Thu, 08/17/17 - 10:36 am
patents
AbbVie
Humira
Pfizer
Lipitor
Norvasc
GSK
Advair
Sanofi
Lantus
JNJ
Remicade
AstraZeneca
Crestor
Nexium
Amgen
Neulasta
Novartis
Diovan
Amgen rolls new Prolia osteoporosis ads, just weeks after next-gen Evenity hits a snag
Fierce Pharma
Wed, 08/16/17 - 09:39 pm
Amgen
Prolia
osteoporosis
drug ads
What Kyprolis Could Do for Amgen’s Revenue Growth
Market Realist
Tue, 08/15/17 - 09:38 am
Kyprolis
Amgen
Multiple Myeloma
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
Motley Fool
Mon, 08/14/17 - 10:03 am
biotech
M&A
JNJ
Actelion
Takeda
Ariad Pharmaceuticals
Gilead Sciences
Pfizer
Amgen
Amgen falls short in Epogen patent appeal but Pfizer stumble delays competition
Fierce Pharma
Fri, 08/11/17 - 11:22 am
Amgen
Epogen
patents
Pfizer
anemia
biosimilars
Amgen Remains A Standout Among Biotechs
Forbes
Tue, 08/8/17 - 11:55 am
Amgen
Repatha
biotech
Cytokinetics inches forward with heart failure program
BioPharma Dive
Thu, 08/3/17 - 10:57 am
Cytokinetics
Omecamtiv Mecarbil
Amgen
heart failure
Japan
As Roche wades biosimilar waters, more competitors circle Herceptin
BioPharma Dive
Wed, 08/2/17 - 09:28 pm
Roche
Herceptin
biosimilars
Amgen
Allergan
ABP 980
Celltrion
CT-P6
FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact
Fierce Pharma
Mon, 07/31/17 - 09:56 pm
FDA
Herceptin
biosimilars
Roche
Amgen
Teva Pharmaceutical
Allergan
Celltrion
With $39B in cash and biosim threats looming, could Amgen use a deal? Executives say not yet
Fierce Pharma
Wed, 07/26/17 - 10:36 pm
Amgen
biosimilars
M&A
Amgen second-quarter profit tops Street view, shares fall
Reuters
Wed, 07/26/17 - 09:54 am
Amgen
earnings
Amgen And Novartis: First Mover Advantage Is A Must
Seeking Alpha
Mon, 07/24/17 - 11:55 pm
Amgen
Novartis
migraines
erenumab
CGRP blockers
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
Yahoo/Zacks.com
Mon, 07/24/17 - 11:14 am
earnings
Eli Lilly
Biogen
Amgen
An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis Landscape
Seeking Alpha
Mon, 07/24/17 - 10:44 am
Amgen
Radius Health
osteoporosis
Tymlos
romosozumab

Pages